Skip to main content

Table 1 Demographic and clinical characteristics of the CAPTURE study population stratified by CVD status in Brazil

From: Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study

Characteristic Study population
N = 912
By CVD status
CVD
n = 400
Non-CVD
n = 512
n Data n Data n Data
Female 912 538 (59.0) 400 190 (47.5) 512 348 (68.0)
Age, years [IQR] 912 64.0 [57.0; 71.0] 400 67.0 [61.0; 72.0] 512 62.0 [55.0; 69.0]
Race 912   400   512  
 White   610 (66.9)   275 (68.8)   335 (65.4)
 Asian   19 (2.1)   12 (3.0)   7 (1.4)
 Black or African American   114 (12.5)   59 (14.8)   55 (10.7)
 Other   169 (18.5)   54 (13.5)   115 (22.5)
Diabetes duration, years [IQR] 912 11.0 [6.0; 19.0] 400 13.2 [7.2; 21.0] 512 10.0 [5.5; 17.0]
HbA1c, % [IQR] 776 7.7 [6.7; 9.1] 323 7.8 [6.8; 9.1] 453 7.6 [6.6; 9.1]
HbA1c, mmol/mol [IQR] 776 60.7 [49.7; 76.0] 323 61.8 [50.8; 76.0] 453 59.6 [48.6; 76.0]
HbA1c 776   323   453  
 < 7%   250 (32.2)   91 (28.2)   159 (35.1)
 7–9%   318 (41.0)   148 (45.8)   170 (37.5)
 ≥ 9%   208 (26.8)   84 (26.0)   124 (27.4)
FPG, mmol/L [IQR] 764 7.7 [6.2; 10.1] 310 8.0 [6.0; 10.2] 454 7.6 [6.2; 9.9]
BMI, kg/m2 [IQR] 907 29.5 [26.4; 33.5] 400 29.8 [26.7; 33.4] 507 29.4 [26.2; 33.7]
Obesity 907   400   507  
 Without obesity   486 (53.6)   206 (51.6)   280 (55.2)
 With obesity   421 (46.4)   194 (48.8)   227 (44.7)
Systolic blood pressure, mmHg [IQR] 912 130.0 [120.0; 147.0] 400 130.0 [120.0; 147.5] 512 130.0 [120; 145.5]
LDL cholesterol, mmol/L[IQR] 692 2.3 [1.8; 3.0] 283 2.1 [1.6; 2.7] 409 2.5 [1.9; 3.2]
HDL cholesterol, mmol/L [IQR] 731 1.1 [0.9; 1.4] 304 1.1 [0.9; 1.3] 427 1.2 [1.0; 1.5]
Triglyceride, mmol/L [IQR] 737 1.8 [1.2; 2.5] 305 1.8 [1.3; 2.6] 432 1.8 [1.2; 2.5]
eGFR, mL/min/1.73 m2 674   281   393  
 > 89   166 (24.6)   46 (16.4)   120 (30.5)
 > 59–89   269 (39.9)   110 (39.1)   159 (40.5)
 > 29–59   193 (28.6)   99 (35.2)   94 (23.9)
 ≤ 29   46 (6.8)   26 (9.3)   20 (5.1)
Albuminuria 412   174   238  
 Normal–mildly increased   243 (59.0)   88 (50.6)   155 (65.1)
 Microalbuminuria   126 (30.6)   70 (40.2)   56 (23.5)
 Macroalbuminuria   43 (10.4)   16 (9.2)   27 (11.3)
Medical history of hypertension, yes 909 735 (80.9) 399 355 (89.0) 510 380 (74.5)
Familial hypercholesterolemia, yes 742 118 (15.9) 342 59 (17.3) 400 59 (14.8)
Retinopathy 912   400   512  
 Yes   143 (15.7)   85 (21.3)   58 (11.3)
 Yes (referred by participant)   50 (5.5)   26 (6.5)   24 (4.7)
 No   719 (78.8)   289 (72.3)   430 (84.0)
Nephropathy 912   400   512  
 Yes   260 (28.5)   138 (34.5)   122 (23.8)
 Yes (referred by participant)   25 (2.7)   14 (3.5)   11 (2.1)
 No   627 (68.8)   248 (62.0)   379 (74.0)
Neuropathy 912   400   512  
 Yes   151 (16.6)   75 (18.8)   76 (14.8)
 Yes (referred by participant)   49 (5.4)   24 (6.0)   25 (4.9)
 No   712 (78.1)   301 (75.3)   411 (80.3)
Smoking status 907   399   508  
 Current   53 (5.8)   27 (6.8)   26 (5.1)
 Previous   270 (29.8)   158 (39.6)   112 (22.0)
 Never   584 (64.4)   214 (53.6)   370 (72.8)
Duration of smoking, years 321 29.0 (0.0; 63.0) 184 30.0 (0.0; 63.0) 137 20.0 (1.0; 60.0)
Physical activity, days per week 839   361   478  
 0–1   515 (61.4)   251 (69.5)   264 (55.2)
 2–3   192 (22.9)   58 (16.1)   134 (28.0)
 4–5   94 (11.2)   38 (10.5)   56 (11.7)
 6–7   38 (4.5)   14 (3.9)   24 (5.0)
  1. Data are n (%) or median [IQR]
  2. BMI: body mass index; CVD: cardiovascular disease; eGFR: estimated glomerular filtration rate; FPG: fasting plasma glucose; HbA1c: glycated hemoglobin; HDL: high-density lipoprotein; IQR: interquartile range; LDL: low-density lipoprotein; N: number of patients in the overall Brazil sample; n: number of patients in each subgroup within the Brazil sample
  3. Only applies to participants categorized as current or previous smokers
  4. Days with ≥ 30 min of moderate activity